United States· US:85006-1754_25c471d4-a4c1-4f99-8848-c49ce5b0000a
ALYMSYS
A medicinal product containing bevacizumab-maly, registered in United States by Valorum Biologics, LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- BEVACIZUMAB-MALY
- Manufacturer
- Valorum Biologics, LLC
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1185006175411 VIAL in 1 CARTON (85006-1754-1) / 4 mL in 1 VIAL
- ndc1185006-1754-1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bevacizumab-maly in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAbevmy
- SpainABEVMY 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBiosimilar Collaborations Ireland Limited
- United KingdomAbevmy 100mg/4ml concentrate for solution for infusion vialsBiocon Biologics Ireland Ltd
- CzechiaABEVMYBiosimilar Collaborations Ireland Limited, Dublin
- BelgiumAbevmy 25 mg/mlBiosimilar Collaborations Ireland
- FinlandAbevmyBiosimilar Collaborations Ireland Limited
- CanadaABEVMYBIOSIMILAR COLLABORATIONS IRELAND LIMITED
- PolandAbevmyBiosimilar Collaborations Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Oyavas
- Iceland · Abevmy, Alymsys
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f3ba662a-87bc-42eb-b9ca-cf45c878f9ed GET /v1/drugs/f3ba662a-87bc-42eb-b9ca-cf45c878f9ed?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "100",
"substance": "BEVACIZUMAB-MALY",
"productndc": "85006-1754",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/4mL",
"application_number": "BLA761231",
"marketing_category": "BLA"
}See everything about bevacizumab-maly.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.